Access

Article


Nature Medicine 11, 867 - 874 (2005)
Published online: 24 July 2005 | doi:10.1038/nm1275

Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach

Alexandre Lautrette1, Shunqiang Li2, Rohia Alili1, Susan W Sunnarborg2, Martine Burtin1, David C Lee2, Gérard Friedlander1 & Fabiola Terzi1


Mechanisms of progression of chronic renal diseases, a major healthcare burden, are poorly understood. Angiotensin II (AngII), the major renin-angiotensin system effector, is known to be involved in renal deterioration, but the molecular pathways are still unknown. Here, we show that mice overexpressing a dominant negative isoform of epidermal growth factor receptor (EGFR) were protected from renal lesions during chronic AngII infusion. Transforming growth factor-alpha (TGF-alpha) and its sheddase, TACE (also known as ADAM17), were induced by AngII treatment, TACE was redistributed to apical membranes and EGFR was phosphorylated. AngII-induced lesions were substantially reduced in mice lacking TGF-alpha or in mice given a specific TACE inhibitor. Pharmacologic inhibition of AngII prevented TGF-alpha and TACE accumulation as well as renal lesions after nephron reduction. These findings indicate a crucial role for AngII-dependent EGFR transactivation in renal deterioration and identify in TACE inhibitors a new therapeutic strategy for preventing progression of chronic renal diseases.


MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Shedding growth factors in cardiac hypertrophy

Nature Medicine News and Views (01 Jan 2002)

$rb.Type.Code